Skip to Content
Merck
  • Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Antimicrobial agents and chemotherapy (2015-09-16)
Liang Sun, Adam Meijer, Mathy Froeyen, Linlin Zhang, Hendrik Jan Thibaut, Jim Baggen, Shyla George, John Vernachio, Frank J M van Kuppeveld, Pieter Leyssen, Rolf Hilgenfeld, Johan Neyts, Leen Delang
ABSTRACT

We investigated the susceptibility of 10 enterovirus D68 (EV-D68) isolates (belonging to clusters A, B, and C) to (entero)virus inhibitors with different mechanisms of action. The 3C-protease inhibitors proved to be more efficient than enviroxime and pleconaril, which in turn were more effective than vapendavir and pirodavir. Favipiravir proved to be a weak inhibitor. Resistance to pleconaril maps to V69A in the VP1 protein, and resistance to rupintrivir maps to V104I in the 3C protease. A structural explanation of why both substitutions may cause resistance is provided.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Enviroxime, ≥98% (HPLC)